EA200100127A1 - Производные фенилксантина - Google Patents

Производные фенилксантина

Info

Publication number
EA200100127A1
EA200100127A1 EA200100127A EA200100127A EA200100127A1 EA 200100127 A1 EA200100127 A1 EA 200100127A1 EA 200100127 A EA200100127 A EA 200100127A EA 200100127 A EA200100127 A EA 200100127A EA 200100127 A1 EA200100127 A1 EA 200100127A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
phenylxanthine
derivatives
medicine
prevention
Prior art date
Application number
EA200100127A
Other languages
English (en)
Other versions
EA004139B1 (ru
Inventor
Сьюзан Мэри Дейлюдж
Синтия Хоулдер Джергенсен
Майкл Тоулар Мартин
Мартин Хауард Остерхаут
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200100127A1 publication Critical patent/EA200100127A1/ru
Publication of EA004139B1 publication Critical patent/EA004139B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к новым соединениям формулы (I)способам их получения, фармацевтическим препаратам, содержащим их, и к их применению в медицине, в частности в профилактике и лечении воспалительных состояний, иммунных расстройств, септического шока, расстройств кровообращения и желудочно-кишечных воспалений и расстройств.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100127A 1998-08-13 1999-08-11 Производные фенилксантина EA004139B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds
PCT/EP1999/005814 WO2000009507A1 (en) 1998-08-13 1999-08-11 Phenyl yanthine derivatives

Publications (2)

Publication Number Publication Date
EA200100127A1 true EA200100127A1 (ru) 2001-10-22
EA004139B1 EA004139B1 (ru) 2004-02-26

Family

ID=10837179

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100127A EA004139B1 (ru) 1998-08-13 1999-08-11 Производные фенилксантина

Country Status (37)

Country Link
US (3) US6608069B1 (ru)
EP (1) EP1104422B1 (ru)
JP (3) JP3631961B2 (ru)
KR (1) KR20010085369A (ru)
CN (2) CN1251676C (ru)
AP (1) AP1408A (ru)
AR (1) AR020154A1 (ru)
AT (1) ATE259810T1 (ru)
AU (1) AU775819B2 (ru)
BR (1) BR9913020A (ru)
CA (1) CA2340350A1 (ru)
CO (1) CO5130007A1 (ru)
DE (1) DE69914921T2 (ru)
DK (1) DK1104422T3 (ru)
EA (1) EA004139B1 (ru)
EE (1) EE04721B1 (ru)
ES (1) ES2215399T3 (ru)
GB (1) GB9817623D0 (ru)
HK (1) HK1035195A1 (ru)
HU (1) HUP0103637A3 (ru)
ID (1) ID28723A (ru)
IL (1) IL141318A0 (ru)
IS (1) IS5843A (ru)
MA (1) MA26673A1 (ru)
MY (1) MY133393A (ru)
NO (1) NO20010715L (ru)
NZ (1) NZ509778A (ru)
PE (1) PE20000952A1 (ru)
PL (1) PL346055A1 (ru)
PT (1) PT1104422E (ru)
SI (1) SI1104422T1 (ru)
SK (1) SK2222001A3 (ru)
TR (1) TR200100448T2 (ru)
TW (1) TWI224598B (ru)
WO (1) WO2000009507A1 (ru)
YU (1) YU11601A (ru)
ZA (1) ZA200101186B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
BR0115474A (pt) * 2000-11-17 2006-01-31 Idenix Cayman Ltd Composição e método para inibição da transmissão de hiv que usam 6-benzil-4-oxopirimidinas substituìdas aplicada por via tópica
ES2262798T3 (es) * 2001-02-28 2006-12-01 Smithkline Beecham Corporation Derivados glicolicos de xantinas para tratar el sindrome del intestino irritable.
WO2003017964A1 (en) 2001-08-24 2003-03-06 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
RU2318824C2 (ru) 2001-11-09 2008-03-10 Си Ви Терапьютикс, Инк. Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
US7495004B2 (en) 2002-06-17 2009-02-24 Glaxo Group Limited Purine derivatives as liver X receptor agonists
PL1658291T3 (pl) * 2003-08-25 2014-03-31 Dogwood Pharmaceuticals Inc Podstawione 8-heteroaryloksantyny
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010039289A2 (en) 2008-05-14 2010-04-08 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
CA2911932A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2014182950A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CN105358152A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
WO2014182951A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (ru) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
WO1995013094A1 (en) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
AU2213697A (en) 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
ES2185837T3 (es) 1996-06-07 2003-05-01 Hoechst Ag Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
WO1999043673A1 (fr) 1998-02-26 1999-09-02 Zenyaku Kogyo Kabushiki Kaisha Derives de 1-aza-indolizine
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2001045703A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
NO20010715L (no) 2001-04-02
IL141318A0 (en) 2002-03-10
BR9913020A (pt) 2001-05-08
AU5732399A (en) 2000-03-06
MY133393A (en) 2007-11-30
JP2004137251A (ja) 2004-05-13
DE69914921D1 (en) 2004-03-25
SI1104422T1 (en) 2004-06-30
ATE259810T1 (de) 2004-03-15
ZA200101186B (en) 2002-02-12
CO5130007A1 (es) 2002-02-27
EA004139B1 (ru) 2004-02-26
AP2001002071A0 (en) 2001-03-31
AP1408A (en) 2005-05-06
WO2000009507A1 (en) 2000-02-24
IS5843A (is) 2001-02-09
HK1035195A1 (en) 2001-11-16
PE20000952A1 (es) 2000-09-29
EE200100083A (et) 2002-06-17
EP1104422A1 (en) 2001-06-06
CN1251676C (zh) 2006-04-19
KR20010085369A (ko) 2001-09-07
US6608069B1 (en) 2003-08-19
DK1104422T3 (da) 2004-06-14
CN1515571A (zh) 2004-07-28
NO20010715D0 (no) 2001-02-12
ES2215399T3 (es) 2004-10-01
EP1104422B1 (en) 2004-02-18
GB9817623D0 (en) 1998-10-07
DE69914921T2 (de) 2004-12-23
AR020154A1 (es) 2002-04-10
HUP0103637A2 (en) 2002-06-29
CA2340350A1 (en) 2000-02-24
JP2004115534A (ja) 2004-04-15
SK2222001A3 (en) 2001-12-03
CN1149215C (zh) 2004-05-12
EE04721B1 (et) 2006-10-16
ID28723A (id) 2001-06-28
TR200100448T2 (tr) 2001-09-21
NZ509778A (en) 2003-08-29
JP3631961B2 (ja) 2005-03-23
TWI224598B (en) 2004-12-01
US20040034020A1 (en) 2004-02-19
HUP0103637A3 (en) 2002-10-28
YU11601A (sh) 2004-03-12
CN1323309A (zh) 2001-11-21
JP2002522542A (ja) 2002-07-23
PT1104422E (pt) 2004-06-30
PL346055A1 (en) 2002-01-14
AU775819B2 (en) 2004-08-19
US6770267B2 (en) 2004-08-03
US20030032804A1 (en) 2003-02-13
MA26673A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
EA200100127A1 (ru) Производные фенилксантина
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
EA199901031A1 (ru) Производные бензимидазола
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
TR200102072T2 (tr) İltihap karşıtı maddeler olarak aromatik çok döngülü bileşimler
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200100872A1 (ru) Композиция валдекоксиба
EA199901015A1 (ru) 4"-замещенные производные 9-деоксо-9а-а3а-9а-гомоэритромицина а
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
EA200500378A1 (ru) Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
EA200101036A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)